Research programme: prostate cancer antibodies - ImmunexAlternative Names: Prostate cancer antibody research programme - Immunex
Latest Information Update: 29 Jul 2002
At a glance
- Originator UroCor
- Developer Amgen; UroCor
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 29 Jul 2002 Immunex was acquired by, and merged into, Amgen.
- 11 Jul 2000 New profile
- 11 Jul 2000 Preclinical development for Prostate cancer in USA (Unknown route)